February 6, 2018
AC Immune to Participate in Two Investor Conferences and Provide Scientific Updates at AAT-AD/PD Conference

December 1, 2017
AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases

November 21, 2017
AC Immune to Host Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases

November 13, 2017
AC Immune SA Reports Third Quarter 2017 Financial Results and Corporate Update

November 2, 2017
AC Immune SA to Receive Milestone Payment for Anti-Tau Antibody Moving into Phase 2 Trial for Alzheimer's Disease

October 24, 2017
AC Immune to Present at Two Investor Conferences and Provide Scientific Updates at CTAD Conference

October 3, 2017
AC Immune Awarded Continuation of 2015 Grant from The Michael J. Fox Foundation for Parkinson's Research

September 12, 2017
AC IMMUNE COMPLETES RECRUITMENT FOR LOW-DOSE COHORT IN WORLD'S FIRST CLINICAL TRIAL FOR ANTI-ABETA VACCINE TARGETING ALZHEIMER'S DISEASE-LIKE CHARACTERISTICS IN INDIVIDUALS WITH DOWN SYNDROME

August 22, 2017
AC IMMUNE DISCOVERS NEXT-GENERATION ANTIBODIES FOCUSED ON NEURODEGENERATIVE DISEASES

August 9, 2017
AC IMMUNE REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS

July 10, 2017
AC IMMUNE PROVIDES SEVEN UPDATES ON ITS PIPELINE AND TECHNOLOGY AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE

June 28, 2017
AC IMMUNE ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING

May 22, 2017
AC IMMUNE AND ESSEX BIO-TECHNOLOGY ANNOUNCE RESEARCH COLLABORATION FOR NEURODEGENERATIVE DISEASES AND NEUROINFLAMMATION

May 11, 2017
AC IMMUNE SA REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS

April 3, 2017
Piramal Imaging and AC Immune present first clinical data for tau PET-imaging tracer at International Alzheimer's Conference

March 23, 2017
AC IMMUNE PROVIDES TWELVE UPDATES ON ITS PIPELINE AT THE INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES

March 17, 2017
AC IMMUNE REPORTS FULL YEAR 2016 FINANCIAL RESULTS AND R&D UPDATE

February 28, 2017
AC IMMUNE PARTNER GENENTECH TO START SECOND PHASE 3 CLINICAL TRIAL FOR ALZHEIMER'S THERAPY CRENEZUMAB

December 9, 2016
AC IMMUNE PARTNER GENENTECH PRESENTS IMPORTANT DATA ON ALZHEIMER'S THERAPY CRENEZUMAB

November 23, 2016
AC IMMUNE APPOINTS EXPERIENCED LIFE SCIENCE PROFESSIONAL AS NEW CHIEF FINANCIAL OFFICER

November 15, 2016
AC Immune SA announces results of annual general meeting

November 11, 2016
AC Immune SA Reports Third Quarter 2016 Results

September 23, 2016
Switzerland's AC Immune Opens For Trading On NASDAQ

September 23, 2016
AC Immune SA Announces Pricing of Upsized Initial Public Offering

September 13, 2016
AC Immune SA Commences Proposed Initial Public Offering of Common Shares

July 7, 2016
AC Immune to receive milestone payment for Anti-Tau Antibody moving into Phase 1 trial for Alzheimer's disease

May 9, 2016
AC Immune raises USD 43.5 million (CHF 42.7 million) in financing round E

April 18, 2016
AC Immune announces a research and development collaboration in neurodegenerative diseases with Biogen

April 5, 2016
AC Immune announces publication of ground-breaking scientific publication on anti-Abeta vaccine in preclinical model of Down syndrome

January 7, 2016
World's first clinical trial for anti-Abeta vaccine targeting Alzheimer's disease-like characteristics in people with Down syndrome

September 23, 2015
AC Immune signs collaboration agreement with Nestlé Institute of Health Sciences to develop Alzheimer's disease diagnostic

July 22, 2015
AC Immune receives milestone payment for crenezumab moving into phase III clinical development in Alzheimer's disease

July 13, 2015
AC Immune receives milestone in Anti-Tau Antibody collaboration with Genentech

February 12, 2015
AC Immune Awarded Grant from The Michael J. Fox Foundation for Parkinson's Research

January 12, 2015
AC Immune Enters into a Worldwide License and Collaboration Agreement for Alzheimer's Disease Therapeutic anti-Tau Vaccines with Janssen Pharmaceuticals, Inc.

July 16, 2014
Crenezumab Phase II cognition data in Alzheimer's disease presented

July 16, 2014
Crenezumab Phase II cognition data in Alzheimer's disease presented

May 12, 2014
AC Immune and Piramal Imaging announce out-licensing agreement for the development of Tau protein diagnostics in Alzheimer's disease

May 12, 2014
AC Immune and Piramal Imaging announce out-licensing agreement for the development of Tau protein diagnostics in Alzheimer's disease

January 9, 2014
AC Immune raises CHF 20 million and initiates world's first anti-pTau vaccine trial for Alzheimer's disease

December 23, 2013
Alzheimer's Prevention Initiative (API) Trial marks milestone

January 31, 2013
AC Immune to discontinue development of ACI-91 small molecule

December 11, 2012
FierceBiotech & Recognition of Prof. Pfeifer's personal qualities

September 19, 2012
AC Immune Named One of "Fierce 15" Leading Biotech Companies of 2012

June 18, 2012
AC Immune and Genentech Enter into Second Antibody Collaboration for Alzheimer's Disease

May 16, 2012
AC Immune Therapy chosen for groundbreaking Alzheimer's Disease Trial in Colombia and USA

January 17, 2012
Development of new medicines for memory impairment

May 9, 2011
AC Immune recieves significant milestone payment from Genentech

May 31, 2010
Prof. Andrea Pfeifer represents Switzerland at the election of the Ernst & Young World Entrepreneur Of Year

January 14, 2010
AC Immune boosts its preclinical Alzheimer's pipeline

October 24, 2009
Prof. Andrea Pfeifer - CEO of AC Immune - awarded Swiss Life Science/High-Tech Entrepreneur of the Year 2009

October 8, 2009
AC Immune and Bayer Schering Pharma collaborate in brain imaging for Alzheimer's Disease

January 26, 2009
AC Immune Shapes its Future as World Economic Forum Technology Pioneer 2009

December 4, 2008
Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development

December 7, 2006
Genentech and AC Immune: Exclusive License Agreement

May 11, 2005
AC Immune raises CHF 21 million in private financing round

AC Immune | Press releases
We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

Press releases

  • 09/23/2016

    Switzerland's AC Immune opens for trading on NASDAQ

  • 09/22/2016

    AC Immune announces pricing of upsized initial public offering

  • 09/13/2016

    AC Immune commences proposed initial public offering of common shares

  • 07/07/2016

    AC Immune to receive milestone payment for Anti-Tau Antibody moving into Phase 1 trial for Alzheimer’s disease

    • AC Immune to receive second milestone payment of CHF14 million under collaboration agreement with Genentech
  • 05/09/2016

    AC Immune raises USD 43.5 million (CHF 42.7 million) in financing round E

  • 04/18/2016

    AC Immune announces a research and development collaboration in neurodegenerative diseases with Biogen

    • R&D collaboration to develop PET-ligands for two protein targets involved in pathogenesis of neurodegenerative diseases - alpha-synuclein and TDP43
  • 04/05/2016

    AC Immune announces publication of ground-breaking scientific publication on anti-Abeta vaccine in preclinical model of Down syndrome

    • Vaccine demonstrates efficacy in established model for Down syndrome
    • Paper published in PLOS ONE, highly respected peer review journal
    • Start of patient recruitment in clinical trial with vaccine for Alzheimer’s characteristics in people with Down syndrome
  • 01/07/2016

    World’s first clinical trial for anti-Abeta vaccine targeting Alzheimer’s disease-like characteristics in people with Down syndrome

    • Studies AC Immune’s ACI-24, the first anti-amyloid vaccine for treatment of Alzheimer’s disease-like characteristics in people with Down syndrome
    • Clinical Study is done in collaboration with University of California San Diego
    • US NIH provides significant funding with an additional grant from the LuMind Research Down Syndrome Foundation
    • Alzheimer’s disease-like characteristics develop in virtually all people with Down syndrome over age 40; majority develops associated dementia over
      age 60
  • 09/23/2015

    AC Immune signs collaboration agreement with Nestlé Institute of Health Sciences to develop Alzheimer’s disease diagnostic

    • Development of minimally invasive Tau diagnostic assay for Alzheimer’s disease
    • Potential to identify Alzheimer’s patients at very early and potentially pre-symptomatic stage of the disease
    • Neurodegenerative expertise endorsed by fourth Tau collaboration
  • 07/22/2015

    AC Immune receives milestone payment for crenezumab moving into phase III clinical development in Alzheimer’s disease

    • Phase III clinical program to evaluate crenezumab in people with prodromal-to-mild Alzheimer’s disease
    • AC Immune receives milestone under 2006 collaboration with Genentech 
  • 07/13/2015

    AC Immune receives milestone in Anti-Tau Antibody collaboration with Genentech

    • Lead candidate selected for further development towards clinical trials
    • Encouraging pre-clinical efficacy, safety and pharmacological properties
  • 02/12/2015

    AC Immune Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research

    • Grant to fund development of Parkinson’s disease diagnostic agent
    • Focuses on alpha-synclein, a key protein in Parkinson’s disease pathology
    • Offers potential of earlier and more accurate diagnosis of Parkinson’s disease
  • 01/12/2015

    AC Immune Enters into a Worldwide License and Collaboration Agreement for Alzheimer’s Disease Therapeutic anti-Tau Vaccines with Janssen Pharmaceuticals, Inc.

    • Exclusive worldwide license agreement potentially worth up to USD 509 million (CHF 500 million*)
    • Three-year joint program to develop therapeutic vaccines for tauopathies
    • Therapeutic vaccines offer the potential to treat Alzheimer’s patients earlier in the disease
  • 07/16/2014

    Crenezumab Phase II cognition data in Alzheimer’s disease presented

    • Two phase II studies in people with mild-to-moderate Alzheimer’s disease over 18 months and a total of 522 patients
    • The proof of concept ABBY study met overall objective of estimating treatment effects and demonstrated positive trends in cognitive endpoints over time, although the study did not meet its co-primary endpoints
    • Larger effects seen in patients with mild disease on high-dose of crenezumab intravenously
    • Acceptable risk benefit profile
    • Next steps to be determined by Roche following further analysis of data
  • 05/12/2014

    AC Immune and Piramal Imaging announce out-licensing agreement for the development of Tau protein diagnostics in Alzheimer’s disease

    • Potential important step towards better diagnosis and clinical management of Alzheimer’s disease
    • Tau diagnostics complement AC Immune’s therapeutic product pipeline
    • Piramal Imaging initiates Tau-PET-Imaging tracer development program
    • Significant License Agreement signals the importance of the development of Alzheimer’s Tau-PET-Imaging tracers 
  • 01/09/2014

    AC Immune raises CHF 20 million and initiates world's first anti-pTau vaccine trial for Alzheimer's disease

    • CHF 20 million round D secured from existing investors
    • World's first Alzheimer's vaccine trial against phospho-Tau hallmark
  • 12/23/2013

    Alzheimer's Prevention Initiative (API) Trial marks milestone

    • Participants now enrolled for major prevention trial in Colombia in cognitively healthy adults
  • 01/31/2013

    AC Immune to discontinue development of ACI-91 small molecule

    • Phase II results do not demonstrate efficacy of ACI-91 in patients with advanced Alzheimer's disease
    • ACI-91 drug in-licensed with different mode-of-action from in-house therapies under development
  • 11/12/2012

    FierceBiotech & Recognition of Prof. Pfeifer's personal qualities

  • 09/19/2012

    AC Immune Named One of "Fierce 15" Leading Biotech Companies of 2012

  • 06/18/2012

    AC Immune and Genentech Enter into Second Antibody Collaboration for Alzheimer’s Disease

    • New antibody program targets Tau protein, a major cause of Alzheimer’s disease
    • License agreement potentially worth more than Swiss Francs 400 Million (approximately USD 418 million*)
    • Continuation of excellent long-term partnership based on development of crenezumab anti-Abeta antibody now in Phase II
    • Goal to develop best-in-class and first-in-class antibodies for treatment and diagnosis of Alzheimer’s disease
  • 05/16/2012

    AC Immune Therapy chosen for groundbreaking Alzheimer´s Disease Trial in Colombia and USA

    • World's first Alzheimer's disease prevention trial before onset of symptoms in highest-risk individuals
    • Trial funded by National Institutes of Health, Banner Alzheimer's Institute and Genentech
    • Antibody discovered by AC Immune and exclusively licensed to Genentech
  • 01/17/2012

    Development of new medicines for memory impairment

  • 05/09/2011

    AC Immune recieves significant milestone payment from Genentech

    •  Start of Phase II trial of anti-Abeta antibody for Alzheimer’s Disease
  • 05/31/2010

    Prof. Andrea Pfeifer represents Switzerland at the election of the Ernst & Young World Entrepreneur Of Year

  • 01/14/2010

    AC Immune boosts its preclinical Alzheimer´s pipeline

    • In-licensing of promising memory enhancer ACI-518 from State University of Moscow to complement Alzheimer´s disease drug pipeline
    • Proprietary Morphomer™ ACI-636 enters preclinical development
  • 10/24/2009

    Prof. Andrea Pfeifer - CEO of AC Immune - awarded Swiss Life Science/High-Tech Entrepreneur of the Year 2009

    • Recognition of personal qualities and successful development of thriving biopharmaceutical company
  • 10/08/2009

    AC Immune and Bayer Schering Pharma collaborate in brain imaging for Alzheimer’s Disease

    • Bayer´s diagnostic will be used in Phase I clinical trial of AC Immune Alzheimer´s vaccine ACI-24
  • 01/26/2009

    AC Immune Shapes its Future as World Economic Forum Technology Pioneer 2009

    • CHF 40 million raised in successful round C
    • Key appointments of Chief Financial Officer and Chief Medical Director
  • 12/04/2008

    Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development

    • AC Immune selected as Technology Pioneer 2009 by the Word Economic Forum
    • Phase II clinical trial for small molecule ACI-91 approved
    • First patient enrolled in phase I study of Anti-Abeta antibody - Milestone payment received from collaborator Genentech
  • 12/07/2006

    Genentech and AC Immune: Exclusive License Agreement

  • 05/11/2005

    AC Immune raises CHF 21 million in private financing round